Do analysts prefer DYNT or FEED?

Given Dynatronics' higher probable upside, equities research analysts clearly believe Dynatronics is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer FEED or BIOL?

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is FEED or BIOL more profitable?

BIOLASE has a net margin of -41.65% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets Nanovibronix -1,093.61% -60.73% -48.48% BIOLASE -41.65% -1,782.73% -55.31%

Do analysts prefer FEED or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FEED or GCTK more profitable?

GlucoTrack has a net margin of 0.00% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets Nanovibronix -1,093.61% -60.73% -48.48% GlucoTrack N/A -2,135.52% -290.22%

Do analysts prefer FEED or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FEED or VERO more profitable?

Venus Concept has a net margin of -92.76% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Nanovibronix -1,093.61% -60.73% -48.48% Venus Concept -92.76% -1,904.25% -85.22%

Do analysts rate FEED or PFSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, FEED or PFSA?

Nanovibronix has higher revenue and earnings than Profusa. Nanovibronix is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanovibronix $1.93M 0.13 -$18.18M -$117.28 N/A Profusa N/A N/A -$35.82M -$5.62 thousand N/A

Is FEED or PFSA more profitable?

Profusa has a net margin of 0.00% compared to Nanovibronix's net margin of -1,093.61%. Profusa's return on equity of 0.00% beat Nanovibronix's return on equity. Company Net Margins Return on Equity Return on Assets Nanovibronix -1,093.61% -60.73% -48.48% Profusa N/A N/A -1,731.09%

Nanovibronix (FEED) Competitors

$0.28 -0.03 (-8.26%)

As of 11/10/2026 02:27 PM Eastern

Compare

FEED vs. DYNT, BIOL, GCTK, VERO, and PFSA

Should you buy Nanovibronix stock or one of its competitors? Nanovibronix's main competitors and comparable companies include Dynatronics (DYNT), BIOLASE (BIOL), GlucoTrack (GCTK), Venus Concept (VERO), and Profusa (PFSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nanovibronix compare to Dynatronics?

Dynatronics (NASDAQ:DYNT) and Nanovibronix (NASDAQ:FEED) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

4.2% of Dynatronics shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 2.9% of Dynatronics shares are owned by insiders. Comparatively, 12.2% of Nanovibronix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Dynatronics has a net margin of -8.35% compared to Nanovibronix's net margin of -1,093.61%. Dynatronics' return on equity of -41.81% beat Nanovibronix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dynatronics	-8.35%	-41.81%	-9.56%
Nanovibronix	-1,093.61%	-60.73%	-48.48%

Dynatronics has higher revenue and earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A
Nanovibronix	$1.93M	0.13	-$18.18M	-$117.28	N/A

Given Dynatronics' higher probable upside, equities research analysts clearly believe Dynatronics is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dynatronics has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

In the previous week, Dynatronics' average media sentiment score of 0.00 equaled Nanovibronix'saverage media sentiment score.

Company	Overall Sentiment
Dynatronics	Neutral
Nanovibronix	Neutral

Summary

Dynatronics beats Nanovibronix on 7 of the 12 factors compared between the two stocks.

How does Nanovibronix compare to BIOLASE?

Nanovibronix (NASDAQ:FEED) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

BIOLASE has a net margin of -41.65% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-1,093.61%	-60.73%	-48.48%
BIOLASE	-41.65%	-1,782.73%	-55.31%

Nanovibronix has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nanovibronix has higher earnings, but lower revenue than BIOLASE. Nanovibronix is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$1.93M	0.13	-$18.18M	-$117.28	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

In the previous week, Nanovibronix's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Company	Overall Sentiment
Nanovibronix	Neutral
BIOLASE	Neutral

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 12.2% of Nanovibronix shares are owned by insiders. Comparatively, 0.3% of BIOLASE shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Nanovibronix beats BIOLASE on 7 of the 12 factors compared between the two stocks.

How does Nanovibronix compare to GlucoTrack?

Nanovibronix (NASDAQ:FEED) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 12.2% of Nanovibronix shares are held by company insiders. Comparatively, 5.9% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Nanovibronix has higher revenue and earnings than GlucoTrack. Nanovibronix is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$1.93M	0.13	-$18.18M	-$117.28	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$275.26	N/A

GlucoTrack has a net margin of 0.00% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-1,093.61%	-60.73%	-48.48%
GlucoTrack	N/A	-2,135.52%	-290.22%

Nanovibronix has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

In the previous week, GlucoTrack had 2 more articles in the media than Nanovibronix. MarketBeat recorded 2 mentions for GlucoTrack and 0 mentions for Nanovibronix. GlucoTrack's average media sentiment score of 1.79 beat Nanovibronix's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Overall Sentiment
Nanovibronix	Neutral
GlucoTrack	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Nanovibronix beats GlucoTrack on 8 of the 12 factors compared between the two stocks.

How does Nanovibronix compare to Venus Concept?

Nanovibronix (NASDAQ:FEED) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Nanovibronix has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 12.2% of Nanovibronix shares are held by insiders. Comparatively, 28.0% of Venus Concept shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Venus Concept has a net margin of -92.76% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-1,093.61%	-60.73%	-48.48%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Nanovibronix has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$1.93M	0.13	-$18.18M	-$117.28	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Venus Concept had 1 more articles in the media than Nanovibronix. MarketBeat recorded 1 mentions for Venus Concept and 0 mentions for Nanovibronix. Nanovibronix's average media sentiment score of 0.00 beat Venus Concept's score of -0.71 indicating that Nanovibronix is being referred to more favorably in the media.

Company	Overall Sentiment
Nanovibronix	Neutral
Venus Concept	Negative

Summary

Nanovibronix beats Venus Concept on 7 of the 13 factors compared between the two stocks.

How does Nanovibronix compare to Profusa?

Nanovibronix (NASDAQ:FEED) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Profusa had 2 more articles in the media than Nanovibronix. MarketBeat recorded 2 mentions for Profusa and 0 mentions for Nanovibronix. Profusa's average media sentiment score of 1.35 beat Nanovibronix's score of 0.00 indicating that Profusa is being referred to more favorably in the news media.

Company	Overall Sentiment
Nanovibronix	Neutral
Profusa	Positive

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 9.8% of Profusa shares are owned by institutional investors. 12.2% of Nanovibronix shares are owned by insiders. Comparatively, 15.0% of Profusa shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nanovibronix has higher revenue and earnings than Profusa. Nanovibronix is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$1.93M	0.13	-$18.18M	-$117.28	N/A
Profusa	N/A	N/A	-$35.82M	-$5.62 thousand	N/A

Nanovibronix has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Profusa has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Profusa has a net margin of 0.00% compared to Nanovibronix's net margin of -1,093.61%. Profusa's return on equity of 0.00% beat Nanovibronix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-1,093.61%	-60.73%	-48.48%
Profusa	N/A	N/A	-1,731.09%

Summary

Nanovibronix and Profusa tied by winning 6 of the 12 factors compared between the two stocks.

Get Nanovibronix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEED vs. The Competition

Export

Metric	Nanovibronix	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$259K	$6.12B	$7.90B	$12.09B
Dividend Yield	N/A	1.69%	2.47%	4.43%
P/E Ratio	0.00	39.10	35.24	29.15
Price / Sales	0.13	5.70	8.47	5.78
Price / Cash	N/A	24.25	22.22	22.66
Price / Book	0.00	4.29	4.40	3.79
Net Income	-$18.18M	$143.25M	$3.50B	$389.59M
7 Day Performance	12.22%	-2.54%	-1.49%	-1.98%
1 Month Performance	-20.00%	-1.43%	-4.55%	-6.70%
1 Year Performance	N/A	1.42%	1.42%	-6.65%

Nanovibronix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEED Nanovibronix	0.0376 of 5 stars	$0.28 -8.3%	N/A	N/A	$259K	$1.93M	N/A	20
DYNT Dynatronics	N/A	N/A	N/A	N/A	$653K	$33.60M	N/A	200
BIOL BIOLASE	N/A	N/A	N/A	N/A	$581K	$48.83M	N/A	160
GCTK GlucoTrack	0.6718 of 5 stars	$0.40 flat	N/A	-99.8%	$474K	N/A	N/A	15	News Coverage Positive News Gap Down
VERO Venus Concept	0.1292 of 5 stars	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEED) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanovibronix (FEED) Competitors

FEED vs. DYNT, BIOL, GCTK, VERO, and PFSA

How does Nanovibronix compare to Dynatronics?

Summary

How does Nanovibronix compare to BIOLASE?

Summary

How does Nanovibronix compare to GlucoTrack?

Summary

How does Nanovibronix compare to Venus Concept?

Summary

How does Nanovibronix compare to Profusa?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanovibronix (FEED) Competitors

FEED vs. DYNT, BIOL, GCTK, VERO, and PFSA

How does Nanovibronix compare to Dynatronics?

Do insiders and institutionals believe in DYNT or FEED?

Is DYNT or FEED more profitable?

Which has stronger earnings & valuation, DYNT or FEED?

Do analysts prefer DYNT or FEED?

Which has more risk & volatility, DYNT or FEED?

Does the media refer more to DYNT or FEED?

Summary

How does Nanovibronix compare to BIOLASE?

Is FEED or BIOL more profitable?

Which has more volatility and risk, FEED or BIOL?

Do analysts prefer FEED or BIOL?

Which has higher earnings and valuation, FEED or BIOL?

Does the media refer more to FEED or BIOL?

Do institutionals and insiders believe in FEED or BIOL?

Summary

How does Nanovibronix compare to GlucoTrack?

Do insiders and institutionals have more ownership in FEED or GCTK?

Which has preferable valuation & earnings, FEED or GCTK?

Is FEED or GCTK more profitable?

Which has more risk & volatility, FEED or GCTK?

Does the media prefer FEED or GCTK?

Do analysts prefer FEED or GCTK?

Summary

How does Nanovibronix compare to Venus Concept?

Which has more volatility & risk, FEED or VERO?

Do insiders & institutionals have more ownership in FEED or VERO?

Is FEED or VERO more profitable?

Which has stronger earnings and valuation, FEED or VERO?

Do analysts prefer FEED or VERO?

Does the media prefer FEED or VERO?

Summary

How does Nanovibronix compare to Profusa?

Do analysts rate FEED or PFSA?

Does the media prefer FEED or PFSA?

Do insiders and institutionals believe in FEED or PFSA?

Which has higher earnings and valuation, FEED or PFSA?

Which has more volatility and risk, FEED or PFSA?

Is FEED or PFSA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools